BRPI0820477A2 - Compostos de benzodiazepinona úteis no tratamento de afecções da pele - Google Patents

Compostos de benzodiazepinona úteis no tratamento de afecções da pele

Info

Publication number
BRPI0820477A2
BRPI0820477A2 BRPI0820477-2A BRPI0820477A BRPI0820477A2 BR PI0820477 A2 BRPI0820477 A2 BR PI0820477A2 BR PI0820477 A BRPI0820477 A BR PI0820477A BR PI0820477 A2 BRPI0820477 A2 BR PI0820477A2
Authority
BR
Brazil
Prior art keywords
treatment
compounds useful
skin disorders
benzodiazepinone compounds
benzodiazepinone
Prior art date
Application number
BRPI0820477-2A
Other languages
English (en)
Inventor
Gary D Glick
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of BRPI0820477A2 publication Critical patent/BRPI0820477A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0820477-2A 2007-11-06 2008-11-06 Compostos de benzodiazepinona úteis no tratamento de afecções da pele BRPI0820477A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98589807P 2007-11-06 2007-11-06
PCT/US2008/082629 WO2009061916A2 (en) 2007-11-06 2008-11-06 Benzodiazepinone compounds useful in the treatment of skin conditions

Publications (1)

Publication Number Publication Date
BRPI0820477A2 true BRPI0820477A2 (pt) 2015-06-16

Family

ID=40588763

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820477-2A BRPI0820477A2 (pt) 2007-11-06 2008-11-06 Compostos de benzodiazepinona úteis no tratamento de afecções da pele

Country Status (15)

Country Link
US (3) US8188072B2 (pt)
EP (1) EP2217576B1 (pt)
JP (1) JP5539212B2 (pt)
KR (1) KR20100083819A (pt)
CN (1) CN101918375A (pt)
AU (1) AU2008323945B2 (pt)
BR (1) BRPI0820477A2 (pt)
CA (1) CA2703005A1 (pt)
IL (1) IL205562A0 (pt)
MX (1) MX2010004857A (pt)
NZ (1) NZ584842A (pt)
RU (1) RU2010122902A (pt)
UA (1) UA99839C2 (pt)
WO (1) WO2009061916A2 (pt)
ZA (1) ZA201002764B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
MXPA01011052A (es) 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
CA2779041A1 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
JP5264716B2 (ja) 2006-06-09 2013-08-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物および方法
JP5383513B2 (ja) 2007-03-09 2014-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物ならびに方法
NZ583689A (en) 2007-09-14 2012-04-27 Univ Michigan F1f0-atpase inhibitors and related methods
NZ584842A (en) 2007-11-06 2012-06-29 Univ Michigan Benzodiazepinone compounds useful in the treatment of skin conditions, in particular, psoriasis
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
JP2013505258A (ja) 2009-09-18 2013-02-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ベンゾジアゼピノン化合物およびそれを使用する治療方法
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
AU2015223035A1 (en) 2014-02-26 2016-09-22 Luma Therapeutics, Inc. Ultraviolet phototherapy apparatuses and methods
US20190168016A1 (en) 2016-02-09 2019-06-06 Luma Therapeutics, Inc. Methods, compositions and apparatuses for treating psoriasis by phototherapy
US20200323793A1 (en) * 2016-06-03 2020-10-15 Avexxin As Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
CN116283521B (zh) * 2023-03-13 2025-02-18 江苏馨瑞香料有限公司 兔耳草醛的制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457405A (en) 1945-09-25 1948-12-28 Monsanto Chemicals Halo nitroparaffin modified aminoplasts
DE1810423U (de) 1960-01-05 1960-04-28 Kaiserslautern Guss Armatur Schornsteinreinigungsverschluss.
US3374264A (en) 1962-10-04 1968-03-19 Hoffmann La Roche N-haloacetyl-anthranilic acids and esters
US3261828A (en) 1962-10-04 1966-07-19 Hoffmann La Roche 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds
US3415814A (en) 1966-09-28 1968-12-10 Sterling Drug Inc 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione
US3384635A (en) 1966-09-28 1968-05-21 Sterling Drug Inc 1, 4-benzodiazepine derivatives
AT280290B (de) 1967-11-24 1970-04-10 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen 1-Phenyl-4-alkyl-3H-1,4-benzodiazepin-2,5-[1H,4H]-dionen
USRE30293E (en) 1969-03-18 1980-06-03 Knoll A.G. Process for preparing 1,5-benzodiazepine-2-ones
US4108852A (en) 1969-03-18 1978-08-22 Knoll Ag. Process for preparing 1,5-benzodiazepine-2-ones
GB1363735A (en) 1970-10-23 1974-08-14 Hoechst Ag Process for the manufacture of benzimidazolones
GB1324469A (en) 1970-10-28 1973-07-25 Knoll Ag Derivatives of benzodiazepines
ZA7464B (en) 1973-01-16 1974-11-27 J Voorhees Treatment of proliferating skin diseases with papavine alkaloids
IE38931B1 (en) 1973-03-09 1978-07-05 Lipha Triazolobenzodiazepines
US4076823A (en) 1977-08-18 1978-02-28 E. R. Squibb & Sons, Inc. Triazolo-2,4-benzodiazepines
JPS59112984A (ja) 1982-12-21 1984-06-29 Shionogi & Co Ltd １，４−ベンゾジアゼピン誘導体
US4495101A (en) 1983-04-28 1985-01-22 American Home Products Corporation Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives
US4551480A (en) 1983-06-21 1985-11-05 Stiefel Laboratories, Inc. Compositions for the treatment of psoriasis
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US5004741A (en) 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
DE3435974A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
FR2591596B1 (fr) 1985-12-13 1988-09-09 Roussel Uclaf Nouvelles 4h-triazolo(4,3-a)(1,4)benzodiazepines, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4751223A (en) 1986-10-14 1988-06-14 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines
US4898861A (en) 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5147872A (en) 1987-06-09 1992-09-15 Golwyn Daniel H Treatment of immunologically based disorders, specifically psoriasis
US4970207A (en) 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5041438A (en) 1989-10-30 1991-08-20 Hoffmann-La Roche Inc. Method for treating retroviral infections with benzodiazepine compounds
US5352671A (en) 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
ATE145208T1 (de) 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical Kondensierte thiophenverbindungen und deren verwendung
BR9200951A (pt) 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
JPH07504908A (ja) 1992-03-16 1995-06-01 メルク　シヤープ　エンド　ドーム　リミテツド ベンゾジアゼピン誘導体，該誘導体を含有する組成物及び治療におけるその使用
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5391566A (en) 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
AU692916B2 (en) 1993-11-22 1998-06-18 Merck & Co., Inc. N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4- benzodiazepines
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5444092A (en) 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
JPH10504545A (ja) 1994-07-29 1998-05-06 藤沢薬品工業株式会社 ベンゾジアゼピン誘導体
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
US5677282A (en) 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5962337A (en) 1995-06-29 1999-10-05 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
RU2096044C1 (ru) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Ветеринарный имплантируемый препарат для регулирования биологического ритма животных
US5776946A (en) 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
US6004942A (en) 1995-08-30 1999-12-21 The Regents Of The University Of California Methods for treating arthritis by administering an apoptosis regulator
US5929069A (en) 1995-09-21 1999-07-27 Institute Of Medicinal Molecular Design, Inc. Compounds activating pharmacological effects of retinoids
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US7351421B2 (en) 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
JP3999819B2 (ja) 1996-12-10 2007-10-31 ゼリア新薬工業株式会社 １，５―ベンゾジアセピン誘導体
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US6080568A (en) 1997-08-19 2000-06-27 Genencor International, Inc. Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis
DE69832984T2 (de) 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US20030044776A1 (en) 1998-09-25 2003-03-06 James A. Dykens Compositions and methods for identifying agents that alter mitochondrial permeability transition pores
FR2785803B1 (fr) 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
US7175953B2 (en) 1999-04-09 2007-02-13 Institute Fuer Diagnostik Forschung Short-warp peptide-dye conjugate as contrast agent for optical diagnostic
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
MXPA01011052A (es) * 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20040176358A1 (en) 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
WO2001004103A1 (en) 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6524623B1 (en) 1999-11-12 2003-02-25 Milton Hodosh Therapeutic compositions and methods of use thereof
AU2001255709A1 (en) 2000-05-11 2001-11-20 Eastman Chemical Company Acylated cyclodextrin guest inclusion complexes
US20020048566A1 (en) 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
AU2002231098A1 (en) 2000-12-15 2002-06-24 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
JP2005503356A (ja) 2001-06-07 2005-02-03 ニューロ３デー 環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用
AU2002332560B2 (en) 2001-08-15 2006-01-19 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
WO2003106628A2 (en) 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
US7150433B2 (en) 2002-08-16 2006-12-19 Toyota Motor Sales, U.S.A., Inc. Aircraft bolster trays
US20040087489A1 (en) 2002-11-06 2004-05-06 Antonio Ruiz Compositions and methods for the treatment of mycobacterial infections
WO2004043362A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Acyl guanidine compounds and use thereof
US7745431B2 (en) 2002-12-03 2010-06-29 Vela Acquisition Corporation Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof
ATE440827T1 (de) 2002-12-04 2009-09-15 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
AU2004255153B2 (en) 2003-05-01 2007-11-22 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005262322B2 (en) 2004-07-01 2012-07-26 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
DE602005006585D1 (de) 2004-07-06 2008-06-19 Acp Advanced Circuit Pursuit A Symmetrischer mischer mit fets
US20060052369A1 (en) 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006053193A2 (en) 2004-11-10 2006-05-18 Garden Guardian, Inc. A device and method for controlling animal behavior
JP2008528448A (ja) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
CA2611031A1 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
EP1742460A1 (en) 2005-06-18 2007-01-10 TTE Germany GmbH Raster distortion correction circuit
US20070105844A1 (en) 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2627757A1 (en) 2005-10-26 2007-05-03 The Regents Of The University Of Michigan Therapeutic compositions and methods
CA2779041A1 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
JP5264716B2 (ja) * 2006-06-09 2013-08-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物および方法
GB0615068D0 (en) 2006-07-28 2006-09-06 Ttp Communications Ltd Digital radio systems
JP5383513B2 (ja) * 2007-03-09 2014-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物ならびに方法
NZ583689A (en) 2007-09-14 2012-04-27 Univ Michigan F1f0-atpase inhibitors and related methods
NZ584842A (en) 2007-11-06 2012-06-29 Univ Michigan Benzodiazepinone compounds useful in the treatment of skin conditions, in particular, psoriasis

Also Published As

Publication number Publication date
EP2217576A4 (en) 2011-08-03
US8188072B2 (en) 2012-05-29
WO2009061916A2 (en) 2009-05-14
IL205562A0 (en) 2010-12-30
US8759340B2 (en) 2014-06-24
US20130274197A1 (en) 2013-10-17
RU2010122902A (ru) 2011-12-20
JP5539212B2 (ja) 2014-07-02
WO2009061916A3 (en) 2009-07-16
UA99839C2 (ru) 2012-10-10
MX2010004857A (es) 2010-07-28
NZ584842A (en) 2012-06-29
CN101918375A (zh) 2010-12-15
EP2217576A2 (en) 2010-08-18
US20120040971A1 (en) 2012-02-16
US20090118244A1 (en) 2009-05-07
AU2008323945B2 (en) 2013-11-28
ZA201002764B (en) 2011-06-29
US8461153B2 (en) 2013-06-11
KR20100083819A (ko) 2010-07-22
JP2011503011A (ja) 2011-01-27
CA2703005A1 (en) 2009-05-14
EP2217576B1 (en) 2016-05-11
AU2008323945A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
ZA201002764B (en) Benzodiazepinone compounds useful in the treatment of skin conditions
EP1983965A4 (en) PHOTODYNAMIC COSMETIC PROCEDURE AND HEALING PROCESS
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
HRP20190031T1 (hr) Sintetski triterpenoidi i postupci njihove upotrebe u liječenju bolesti
BRPI0907135A2 (pt) Processos de tratamento de dor crônica
EP2046315A4 (en) THERAPEUTIC AGENTS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES
SI2084151T1 (sl) Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloških bolezni
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0916125A2 (pt) "dispositivo de tratamento"
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
PL2282675T3 (pl) System do zabiegu kosmetycznego i obrazowania
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
EP2205236A4 (en) NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
EP3381471C0 (en) PAIN TREATMENT
DK1863899T3 (da) Hudbehandlingspræparater
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
PL381862A1 (pl) Zastosowanie związków pirydyniowych i sposób leczenia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.